Vesta Medical VestaBlate uterine balloon system begins U.S. clinicals.
This article was originally published in The Gray Sheet
Executive Summary
VESTA MEDICAL VESTABLATE UTERINE BALLOON SYSTEM U.S. CLINICALS begin with first treatment Jan. 31, the Mountain View, California-based firm reports. Under an investigational device exemption approved by FDA in September 1995, Vesta is studying the device as a non-surgical alternative to hysterectomy for the treatment of excessive menstrual bleeding (menorrhagia). Vesta plans to treat 180 patients at up to 12 clinical sites in the U.S.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.